NewsBenzingaUBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94 UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94 Benzinga 2026.10.15 21:05 (GMT+0) Open on Benzinga Other news Homebuilder Sentiment Hits 2012 Lows As Stocks Trade Like They Did During COVID-19 Pandemic Rain Says Western Union's Stablecard Is Live in 37 Markets FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated Nvidia Researchers Using Supercomputer Jupiter For Fault-Tolerant Computing Simulation Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success SpaceX Stock Shakeup: Elon Musk’s Stock Giveaway Meets Insider Sales
